140410 — Mezzion Pharma Co Share Price
0.000.00%
Last trade - 00:00- KR₩1tn
- KR₩1tn
- KR₩32bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.71 | ||
| Price to Tang. Book | 27.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 43.62 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.5% | ||
| Return on Equity | -25.52% | ||
| Operating Margin | -52.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 17,920.42 | 28,634.18 | 26,653.87 | 30,726.18 | 31,720.93 | n/a | n/a | 10.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mezzion Pharma Co., Ltd. is a Korea-based company engaged in the pharmaceutical business. The Company focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The Company has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
Directors
- Dong Hyeon Park CEO (56)
- Mu Hui Yoo MDR (61)
- Dae Sik Oh OTH (65)
- Won Bae Kim DRC (65)
- Dong Wuk Park DRC (59)
- James Yeager DRC (67)
- Dong Hun Lee NID (55)
- Cheol Sik Shin NID (58)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 25th, 2002
- Public Since
- January 20th, 2012
- No. of Shareholders
- 33,523
- No. of Employees
- 24
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 29,792,127
- Address
- 3F, C&H Bldg, SEOUL, 06163
- Web
- https://www.mezzion.co.kr/
- Phone
- +82 25608000
- Auditors
- Ernst & Young Han Young
Upcoming Events for 140410
Q3 2024 Mezzion Pharma Co Ltd Earnings Release
Similar to 140410
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
Ahn-Gook Pharmaceutical Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
What is the Mezzion Pharma Co share price?
As of Today at 16:04 UTC, shares in Mezzion Pharma Co are trading at KR₩38,200. This share price information is delayed by 15 minutes.
How has the Mezzion Pharma Co share price performed this year?
Shares in Mezzion Pharma Co last closed at KR₩38,200 and the price had moved by +7.03% over the past 365 days. In terms of relative price strength the Mezzion Pharma Co share price has outperformed the FTSE Developed Asia Pacific Index by +2.42% over the past year.
What are the analyst and broker recommendations for Mezzion Pharma Co?
The overall consensus recommendation for Mezzion Pharma Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mezzion Pharma Co dividend yield?
Mezzion Pharma Co does not currently pay a dividend.
Does Mezzion Pharma Co pay a dividend?
Mezzion Pharma Co does not currently pay a dividend.
When does Mezzion Pharma Co next pay dividends?
Mezzion Pharma Co does not currently pay a dividend.
How do I buy Mezzion Pharma Co shares?
To buy shares in Mezzion Pharma Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mezzion Pharma Co?
As of the previous close price of KR₩38,200, shares in Mezzion Pharma Co had a market capitalisation of KR₩1tn.
Where are Mezzion Pharma Co shares listed?
Here are the trading details for Mezzion Pharma Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 140410
What kind of share is Mezzion Pharma Co?
Based on an overall assessment of its quality, value and momentum Mezzion Pharma Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mezzion Pharma Co share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Mezzion Pharma Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mezzion Pharma Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +2.37%.
As of the last closing price of KR₩38,200, shares in Mezzion Pharma Co were trading -2.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mezzion Pharma Co PE Ratio?
The Mezzion Pharma Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩38,200.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mezzion Pharma Co?
Mezzion Pharma Co's management team is headed by:
- Dong Hyeon Park - CEO
- Mu Hui Yoo - MDR
- Dae Sik Oh - OTH
- Won Bae Kim - DRC
- Dong Wuk Park - DRC
- James Yeager - DRC
- Dong Hun Lee - NID
- Cheol Sik Shin - NID